American Trust Has $3.83 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

American Trust cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,595 shares of the medical research company’s stock after selling 46 shares during the quarter. American Trust’s holdings in Thermo Fisher Scientific were worth $3,833,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in TMO. Cypress Asset Management Inc. TX lifted its stake in Thermo Fisher Scientific by 9.7% during the first quarter. Cypress Asset Management Inc. TX now owns 2,886 shares of the medical research company’s stock worth $1,705,000 after purchasing an additional 254 shares during the period. EverSource Wealth Advisors LLC lifted its stake in Thermo Fisher Scientific by 5.0% during the first quarter. EverSource Wealth Advisors LLC now owns 1,377 shares of the medical research company’s stock worth $784,000 after purchasing an additional 65 shares during the period. Westwood Holdings Group Inc. lifted its stake in Thermo Fisher Scientific by 54.9% during the first quarter. Westwood Holdings Group Inc. now owns 1,233 shares of the medical research company’s stock worth $717,000 after purchasing an additional 437 shares during the period. DekaBank Deutsche Girozentrale lifted its stake in Thermo Fisher Scientific by 10.2% during the first quarter. DekaBank Deutsche Girozentrale now owns 767,218 shares of the medical research company’s stock worth $442,884,000 after purchasing an additional 71,066 shares during the period. Finally, Pathway Financial Advisers LLC bought a new position in Thermo Fisher Scientific during the first quarter worth about $824,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Down 1.0 %

TMO traded down $6.08 during trading on Friday, reaching $615.69. 1,564,731 shares of the company’s stock were exchanged, compared to its average volume of 1,701,727. The company’s fifty day moving average price is $565.52 and its 200-day moving average price is $568.26. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $622.30. The firm has a market capitalization of $235.02 billion, a PE ratio of 39.49, a P/E/G ratio of 2.89 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The company had revenue of $10.54 billion during the quarter, compared to analyst estimates of $10.50 billion. During the same quarter in the previous year, the business earned $5.15 EPS. The firm’s revenue was down 1.4% on a year-over-year basis. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.71 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.25%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $70,238,340.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $180,255.00. Following the sale, the executive vice president now directly owns 17,887 shares of the company’s stock, valued at approximately $10,747,403.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $70,238,340.48. The disclosure for this sale can be found here. Insiders sold 33,084 shares of company stock valued at $19,767,092 in the last quarter. Company insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on TMO. Robert W. Baird lifted their target price on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. JPMorgan Chase & Co. lifted their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research note on Thursday, April 25th. Evercore ISI cut their target price on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. HSBC lifted their target price on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Finally, Stifel Nicolaus lifted their target price on shares of Thermo Fisher Scientific from $600.00 to $615.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $618.94.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.